Lyell Immunopharma (LYEL) Stock Forecast, Price Target & Predictions
LYEL Stock Forecast
Lyell Immunopharma stock forecast is as follows: an average price target of $6.67 (represents a 547.57% upside from LYEL’s last price of $1.03) and a rating consensus of 'Hold', based on 3 wall street analysts offering a 1-year stock forecast.
LYEL Price Target
The average price target for Lyell Immunopharma (LYEL) is $6.67 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $12.00 to $1.00. This represents a potential 547.57% upside from LYEL's last price of $1.03.
LYEL Analyst Ratings
According to 3 Wall Street analysts, Lyell Immunopharma's rating consensus is 'Hold'. The analyst rating breakdown for LYEL stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 3 'Hold' (100.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Lyell Immunopharma Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 30, 2024 | Geoff Meacham | Bank of America Securities | $1.00 | $0.95 | 5.47% | -2.91% |
| Nov 14, 2022 | - | Morgan Stanley | $7.00 | $4.53 | 54.53% | 579.61% |
| May 24, 2022 | - | Goldman Sachs | $12.00 | $4.01 | 199.25% | 1065.05% |
The latest Lyell Immunopharma stock forecast, released on Oct 30, 2024 by Geoff Meacham from Bank of America Securities, set a price target of $1.00, which represents a 5.47% increase from the stock price at the time of the forecast ($0.95), and a -2.91% decrease from LYEL last price ($1.03).
Lyell Immunopharma Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 1 |
| Avg Price Target | $1.00 | $1.00 | $1.00 |
| Last Closing Price | $1.03 | $1.03 | $1.03 |
| Upside/Downside | -2.91% | -2.91% | -2.91% |
In the current month, the average price target of Lyell Immunopharma stock is $1.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a -2.91% decrease as opposed to Lyell Immunopharma's last price of $1.03. This month's average price target is down 0.00% compared to last quarter, and down 0.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 28, 2024 | H.C. Wainwright | Neutral | Neutral | Hold |
| Jun 27, 2024 | H.C. Wainwright | - | Neutral | Downgrade |
| Nov 14, 2022 | Morgan Stanley | - | Equal-Weight | Downgrade |
| Nov 11, 2022 | Goldman Sachs | Buy | Neutral | Downgrade |
| May 24, 2022 | Goldman Sachs | Buy | Buy | Hold |
Lyell Immunopharma's last stock rating was published by H.C. Wainwright on Oct 28, 2024. The company gave LYEL a "Neutral" rating, the same as its previous rate.
Lyell Immunopharma Financial Forecast
Lyell Immunopharma Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | $27.00K | $65.00K | $48.39K | $3.00K | $35.74M | $553.00K | $2.82M | $2.75M | $2.63M |
| Avg Forecast | $49.19K | $45.68K | $42.43K | $39.41K | $36.60K | $34.00K | $3.25K | $1.00K | $3.25K | $6.25K | $18.00K | $-17.50K | $16.13M | $1.80M | $17.87M | $776.50K | $2.64M | $2.88M | $2.31M |
| High Forecast | $49.19K | $45.68K | $42.43K | $39.41K | $36.60K | $34.00K | $3.25K | $1.00K | $6.47K | $6.25K | $18.00K | $-17.50K | $16.13M | $1.80M | $17.87M | $776.50K | $2.64M | $2.88M | $2.31M |
| Low Forecast | $49.19K | $45.68K | $42.43K | $39.41K | $36.60K | $34.00K | $3.25K | $1.00K | $19.00 | $6.25K | $18.00K | $-17.50K | $16.13M | $1.80M | $17.87M | $776.50K | $2.64M | $2.88M | $2.31M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 1.50% | -3.71% | 0.00% | 0.00% | 2.00% | 0.71% | 1.07% | 0.96% | 1.14% |
Lyell Immunopharma's average Quarter revenue forecast for Sep 23 based on 1 analysts is $6.25K, with a low forecast of $6.25K, and a high forecast of $6.25K. LYEL's average Quarter revenue forecast represents a -76.85% decrease compared to the company's last Quarter revenue of $27.00K (Jun 23).
Lyell Immunopharma EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | $-57.92M | $-47.53M | $-3.36K | $-56.82M | $-33.09M | $-64.39M | $-79.14M | $-44.78M | $-59.59M |
| Avg Forecast | $-49.19K | $-45.68K | $-42.43K | $-39.41K | $-36.60K | $-34.00K | $-3.25K | $-1.00K | $-3.25K | $-6.25K | $-18.00K | $17.50K | $-16.13M | $-1.80M | $-17.87M | $-65.75M | $-2.64M | $-2.88M | $-70.81M |
| High Forecast | $-49.19K | $-45.68K | $-42.43K | $-39.41K | $-36.60K | $-34.00K | $-3.25K | $-1.00K | $-19.00 | $-6.25K | $-18.00K | $17.50K | $-16.13M | $-1.80M | $-17.87M | $-52.60M | $-2.64M | $-2.88M | $-56.64M |
| Low Forecast | $-49.19K | $-45.68K | $-42.43K | $-39.41K | $-36.60K | $-34.00K | $-3.25K | $-1.00K | $-6.47K | $-6.25K | $-18.00K | $17.50K | $-16.13M | $-1.80M | $-17.87M | $-78.90M | $-2.64M | $-2.88M | $-84.97M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 3217.78% | -2715.94% | 0.00% | 31.56% | 1.85% | 0.98% | 29.95% | 15.56% | 0.84% |
undefined analysts predict LYEL's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Lyell Immunopharma's previous annual EBITDA (undefined) of $NaN.
Lyell Immunopharma Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | $-63.89M | $-132.63M | $2.44M | $-74.07M | $-35.38M | $-67.71M | $-83.38M | $-48.60M | $-62.38M |
| Avg Forecast | $-58.95M | $-55.11M | $-49.98M | $-48.70M | $-49.34M | $-49.98M | $-50.62M | $-56.39M | $-58.95M | $-62.03M | $-67.28M | $-66.00M | $-58.31M | $-79.45M | $-55.97M | $-70.49M | $-69.07M | $-120.04M | $-74.38M |
| High Forecast | $-58.95M | $-55.11M | $-49.98M | $-46.38M | $-44.41M | $-49.98M | $-50.62M | $-56.39M | $-50.53M | $-62.03M | $-67.28M | $-66.00M | $-58.31M | $-79.45M | $-55.97M | $-56.40M | $-69.07M | $-120.04M | $-59.51M |
| Low Forecast | $-58.95M | $-55.11M | $-49.98M | $-48.70M | $-54.27M | $-49.98M | $-50.62M | $-56.39M | $-72.99M | $-62.03M | $-67.28M | $-66.00M | $-58.31M | $-79.45M | $-55.97M | $-84.59M | $-69.07M | $-120.04M | $-89.26M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.95% | 2.01% | -0.04% | 0.93% | 0.63% | 0.96% | 1.21% | 0.40% | 0.84% |
Lyell Immunopharma's average Quarter net income forecast for Mar 23 is $-66.00M, with a range of $-66.00M to $-66.00M. LYEL's average Quarter net income forecast represents a -2806.45% decrease compared to the company's last Quarter net income of $2.44M (Dec 22).
Lyell Immunopharma SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | $19.03M | $19.28M | $26.35K | $26.08M | $30.45M | $34.42M | $31.87M | $21.24M | $19.11M |
| Avg Forecast | $5.81M | $5.40M | $5.01M | $4.66M | $4.32M | $4.02M | $383.91K | $118.13K | $383.91K | $738.29K | $2.13M | $-2.07M | $1.91B | $212.63M | $2.11B | $91.73M | $312.16M | $339.91M | $273.35M |
| High Forecast | $5.81M | $5.40M | $5.01M | $4.66M | $4.32M | $4.02M | $383.91K | $118.13K | $764.64K | $738.29K | $2.13M | $-2.07M | $1.91B | $212.63M | $2.11B | $91.73M | $312.16M | $339.91M | $273.35M |
| Low Forecast | $5.81M | $5.40M | $5.01M | $4.66M | $4.32M | $4.02M | $383.91K | $118.13K | $2.24K | $738.29K | $2.13M | $-2.07M | $1.91B | $212.63M | $2.11B | $91.73M | $312.16M | $339.91M | $273.35M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 8.95% | -9.33% | 0.00% | 0.12% | 0.01% | 0.38% | 0.10% | 0.06% | 0.07% |
Lyell Immunopharma's average Quarter SG&A projection for Sep 23 is $738.29K, based on 1 Wall Street analysts, with a range of $738.29K to $738.29K. The forecast indicates a -96.12% fall compared to LYEL last annual SG&A of $19.03M (Jun 23).
Lyell Immunopharma EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | $-0.26 | $-0.53 | $0.01 | $-0.30 | $-0.14 | $-0.28 | $-0.35 | $-0.20 | $-1.46 |
| Avg Forecast | $-0.23 | $-0.21 | $-0.20 | $-0.19 | $-0.19 | $-0.20 | $-0.20 | $-0.22 | $-0.23 | $-0.24 | $-0.26 | $-0.26 | $-0.23 | $-0.31 | $-0.22 | $-0.28 | $-0.27 | $-0.47 | $-0.38 |
| High Forecast | $-0.23 | $-0.21 | $-0.20 | $-0.18 | $-0.17 | $-0.20 | $-0.20 | $-0.22 | $-0.20 | $-0.24 | $-0.26 | $-0.26 | $-0.23 | $-0.31 | $-0.22 | $-0.28 | $-0.27 | $-0.47 | $-0.38 |
| Low Forecast | $-0.23 | $-0.21 | $-0.20 | $-0.19 | $-0.21 | $-0.20 | $-0.20 | $-0.22 | $-0.28 | $-0.24 | $-0.26 | $-0.26 | $-0.23 | $-0.31 | $-0.22 | $-0.28 | $-0.27 | $-0.47 | $-0.38 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.99% | 2.06% | -0.04% | 0.96% | 0.64% | 1.01% | 1.29% | 0.43% | 3.89% |
According to 1 Wall Street analysts, Lyell Immunopharma's projected average Quarter EPS for Mar 23 is $-0.26, with a low estimate of $-0.26 and a high estimate of $-0.26. This represents a -2701.01% decrease compared to LYEL previous annual EPS of $0.01 (Dec 22).
Lyell Immunopharma Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| IPSC | Century Therapeutics | $1.26 | $15.00 | 1090.48% | Buy |
| STTK | Shattuck Labs | $1.11 | $12.00 | 981.08% | Hold |
| NKTX | Nkarta | $2.50 | $21.60 | 764.00% | Buy |
| LYEL | Lyell Immunopharma | $1.03 | $6.67 | 547.57% | Hold |
| CCCC | C4 Therapeutics | $4.05 | $13.50 | 233.33% | Buy |
| SANA | Sana Bio | $2.53 | $8.00 | 216.21% | Buy |
| NUVB | Nuvation Bio | $2.58 | $6.75 | 161.63% | Buy |
| CGEM | Cullinan Oncology | $12.58 | $31.50 | 150.40% | Buy |
| MLYS | Mineralys Therapeutics | $12.60 | $30.00 | 138.10% | Buy |
| KRON | Kronos Bio | $0.86 | $1.63 | 89.53% | Buy |
| MRUS | Merus | $42.93 | $77.13 | 79.66% | Buy |
| EWTX | Edgewise Therapeutics | $31.95 | $45.00 | 40.85% | Buy |
| CRNX | Crinetics Pharmaceuticals | $56.07 | $70.14 | 25.09% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $57.07 | $60.63 | 6.24% | Buy |